featured
Addition of Daratumumab to Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Lancet Haematol 2023 Sep 11;[EPub Ahead of Print], PM Voorhees, DW Sborov, J Laubach, JL Kaufman, B Reeves, C Rodriguez, A Chari, R Silbermann, LJ Costa, LD Anderson, N Nathwani, N Shah, N Bumma, YA Efebera, SA Holstein, C Costello, A Jakubowiak, TM Wildes, RZ Orlowski, KH Shain, AJ Cowan, S Dinner, H Pei, A Cortoos, S Patel, TS Lin, SZ Usmani, PG RichardsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.